Nexlizet Patent Expiration

Nexlizet is a drug owned by Esperion Therapeutics Inc. It is protected by 11 US drug patents filed from 2020 to 2024. Out of these, 6 drug patents are active and 5 have expired. Nexlizet's patents have been open to challenges since 22 February, 2024. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 19, 2040. Details of Nexlizet's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US11613511 Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

Active
US7335799 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2030

(6 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11926584 Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

Active
US11760714 Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

Active
US10912751 Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

Active
US11744816 Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

Active
US9000041 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(9 months ago)

Expired
US9624152 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(9 months ago)

Expired
US10118881 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(9 months ago)

Expired
US10941095 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(9 months ago)

Expired
US8497301 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(9 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nexlizet's patents.

Given below is the list of recent legal activities going on the following patents of Nexlizet.

Activity Date Patent Number
Patent litigations
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 12 Jul, 2024 US10912751
Mail O.P. Petition Decision 17 Jun, 2024 US7335799
Email Notification 17 Jun, 2024 US7335799
Mail-Record Petition Decision of Granted to Make Entity Status large 13 Jun, 2024 US7335799
Record Petition Decision of Granted to Make Entity Status large 12 Jun, 2024 US7335799
O.P. Petition Decision 12 Jun, 2024 US7335799
Patent Term Extension Certificate 13 May, 2024 US7335799
Notice of Final Determination -Eligible 04 Apr, 2024 US7335799
Email Notification 12 Mar, 2024 US11926584
Mail Patent eGrant Notification 12 Mar, 2024 US11926584


FDA has granted several exclusivities to Nexlizet. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Nexlizet, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Nexlizet.

Exclusivity Information

Nexlizet holds 4 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Nexlizet's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 26, 2023
New Chemical Entity Exclusivity(NCE) Feb 21, 2025
New Indication(I-943) Mar 22, 2027
New Indication(I-945) Mar 22, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Nexlizet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nexlizet's family patents as well as insights into ongoing legal events on those patents.

Nexlizet's Family Patents

Nexlizet has patent protection in a total of 24 countries. It's US patent count contributes only to 40.6% of its total global patent coverage. Click below to unlock the full patent family tree for Nexlizet.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Nexlizet's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 19, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Nexlizet Generics:

There are no approved generic versions for Nexlizet as of now.

Alternative Brands for Nexlizet

Nexlizet which is used for lowering LDL cholesterol and treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Esperion Theraps Inc
Nexletol Used for lowering LDL-C in patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease.





About Nexlizet

Nexlizet is a drug owned by Esperion Therapeutics Inc. It is used for lowering LDL cholesterol and treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Nexlizet uses Bempedoic Acid; Ezetimibe as an active ingredient. Nexlizet was launched by Esperion Theraps Inc in 2020.

Approval Date:

Nexlizet was approved by FDA for market use on 26 February, 2020.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Nexlizet is 26 February, 2020, its NCE-1 date is estimated to be 22 February, 2024.

Active Ingredient:

Nexlizet uses Bempedoic Acid; Ezetimibe as the active ingredient. Check out other Drugs and Companies using Bempedoic Acid; Ezetimibe ingredient

Treatment:

Nexlizet is used for lowering LDL cholesterol and treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease.

Dosage:

Nexlizet is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
180MG;10MG TABLET Prescription ORAL